Microbio Co., Ltd. (TPEX:4128)
Taiwan · Delayed Price · Currency is TWD 17.15
-0.60 (-3.38%)
Apr 17, 2026, 1:30 PM CST
Microbio Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 1,831 | 1,672 | 1,554 | 1,690 | 1,745 |
Other Revenue | 62.92 | 51.23 | 37.47 | 31.44 | 37 |
| 1,894 | 1,723 | 1,591 | 1,722 | 1,782 | |
Revenue Growth (YoY) | 9.94% | 8.26% | -7.58% | -3.38% | 11.28% |
Cost of Revenue | 1,141 | 1,047 | 987.51 | 1,031 | 1,043 |
Gross Profit | 753.46 | 676.08 | 603.88 | 691.3 | 739.37 |
Selling, General & Admin | 793.85 | 738.84 | 705.86 | 536.69 | 1,041 |
Research & Development | 366.71 | 388.66 | 404.49 | 264.91 | 861.54 |
Other Operating Expenses | - | - | - | - | -0.35 |
Operating Expenses | 1,161 | 1,127 | 1,110 | 801.61 | 1,902 |
Operating Income | -407.11 | -451.42 | -506.47 | -110.31 | -1,163 |
Interest Expense | -11.73 | -10.13 | -7.38 | -6.1 | -6.22 |
Interest & Investment Income | 73.34 | 89.14 | 92.55 | 47.4 | 40.85 |
Earnings From Equity Investments | -571.46 | -933.23 | -1,052 | 235.94 | 719.45 |
Currency Exchange Gain (Loss) | -22.76 | 17.26 | 23.33 | 124.45 | -40.11 |
Other Non Operating Income (Expenses) | 3.67 | 8.32 | 5.31 | 8.7 | 14.45 |
EBT Excluding Unusual Items | -936.04 | -1,280 | -1,445 | 300.08 | -434.35 |
Gain (Loss) on Sale of Investments | -14.17 | -3.21 | 65.97 | 22.39 | -8.19 |
Gain (Loss) on Sale of Assets | 6.68 | 4.6 | -0.01 | -171.46 | -1.43 |
Asset Writedown | -8.54 | - | - | - | 3.7 |
Other Unusual Items | 0.49 | 0.27 | 0.98 | 0.82 | 208.4 |
Pretax Income | -951.58 | -1,278 | -1,378 | 151.83 | -231.87 |
Income Tax Expense | 1.96 | 0.17 | -0.55 | -0.6 | 1.29 |
Earnings From Continuing Operations | -953.54 | -1,279 | -1,377 | 152.42 | -233.16 |
Minority Interest in Earnings | 195.79 | 177.76 | 197.44 | 58.77 | 282.58 |
Net Income | -757.75 | -1,101 | -1,180 | 211.2 | 49.42 |
Net Income to Common | -757.75 | -1,101 | -1,180 | 211.2 | 49.42 |
Net Income Growth | - | - | - | 327.33% | -92.56% |
Shares Outstanding (Basic) | 588 | 588 | 588 | 588 | 573 |
Shares Outstanding (Diluted) | 588 | 588 | 588 | 588 | 573 |
Shares Change (YoY) | - | - | 0.05% | 2.55% | 4.78% |
EPS (Basic) | -1.29 | -1.87 | -2.01 | 0.36 | 0.09 |
EPS (Diluted) | -1.29 | -1.87 | -2.01 | 0.36 | 0.09 |
EPS Growth | - | - | - | 316.73% | -92.89% |
Free Cash Flow | 24.49 | 507.32 | -163.53 | 102.69 | -33.24 |
Free Cash Flow Per Share | 0.04 | 0.86 | -0.28 | 0.17 | -0.06 |
Dividend Per Share | - | - | - | 0.035 | 0.032 |
Dividend Growth | - | - | - | 9.43% | - |
Gross Margin | 39.78% | 39.24% | 37.95% | 40.15% | 41.49% |
Operating Margin | -21.49% | -26.20% | -31.83% | -6.41% | -65.25% |
Profit Margin | -40.01% | -63.89% | -74.14% | 12.27% | 2.77% |
Free Cash Flow Margin | 1.29% | 29.45% | -10.28% | 5.96% | -1.86% |
EBITDA | -310.32 | -350.3 | -408.42 | -11.91 | -1,033 |
EBITDA Margin | -16.38% | -20.33% | -25.66% | -0.69% | -57.95% |
D&A For EBITDA | 96.8 | 101.12 | 98.05 | 98.4 | 129.98 |
EBIT | -407.11 | -451.42 | -506.47 | -110.31 | -1,163 |
EBIT Margin | -21.49% | -26.20% | -31.83% | -6.41% | -65.25% |
Revenue as Reported | 1,894 | 1,723 | 1,591 | 1,722 | 1,782 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.